PERK and eIF2α activation are increasingly recognised in postmortem analyses of patients with neurodegenerative disorders, including Alzheimer’s disease, the tauopathies and prion disorders. This evidence concerns the gene EIF2AK3 and early-onset autosomal dominant Alzheimer disease.